# US 2026/0092079 A1 · Manufacture method for aqueous formulation of manganese-containing coordination complex, formulation, and method of treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092079 A1
- Document ID: US20260092079A1
- Status: Published application
- Kind: A1
- Application number: 19/348,626
- Filed: 2025-10-02
- Published: 2026-04-02
- Earliest claimed: 2019-10-10
- Applicants: Galera Labs, LLC
- Inventors: Robert A. BEARDSLEY; Jeffrey A. SCHOLTEN; James BLACKLEDGE; Dennis P. RILEY; Otto F. SCHALL; Robert MCKEAN
- Web page: https://patentgrep.com/patent/US20260092079A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- C07F 13/00: Compounds containing elements of Groups 7 or 17 of the Periodic Table
- A61K 33/32: Manganese; Compounds thereof
- A61K 47/02: Inorganic compounds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

A method is provided for manufacturing an aqueous formulation of a manganese-containing coordination complex, by combining a source of the manganese-containing coordination complex with a source of chloride anion in an aqueous solution, and simultaneously with or following combination of the source of chloride anion and the source of manganese-containing coordination complex in the aqueous solution, providing a source of a dianion to the aqueous solution to form the aqueous formulation.

## Claims

### Claim 1

A method of manufacturing an aqueous formulation of a manganese-containing coordination complex, the aqueous formulation comprising the manganese-containing coordination complex, a chloride anion, and a dianion, the method comprising:
combining a source of the manganese-containing coordination complex with a source of chloride anion in an aqueous solution; and
simultaneously with or following combination of the source of chloride anion and the source of manganese-containing coordination complex in the aqueous solution, providing a source of a dianion to the aqueous solution to form the aqueous formulation,
wherein an amount of the source of chloride anion that is combined with the manganese-containing coordination complex is sufficient to provide a concentration of chloride ion in the aqueous formulation that is in excess of a concentration of dianion in the aqueous formulation, and
wherein the manganese-containing coordination complex comprises a pentaaza macrocyclic ring complex having a structure according to Formula (I)
wherein
M is Mn2+ or Mn3+;
R1, R2, R′2, R3, R4, R5, R′5, R6, R′6, R7, R8, R9, R′9, and R10 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclyl, an amino acid side chain moiety, or a moiety selected from the group consisting of —OR11, —NR11R12, —COR11, —CO2R11, —CONR11R12, —SR11, —SOR11, —SO2R11, —SO2NR11R12, —N(OR11)(R12), —P(O)(OR11)(OR12), —P(O)(OR11)(R12), and —OP(O)(OR11)(OR12), wherein R11 and R12 are independently hydrogen or alkyl;
U, together with the adjacent carbon atoms of the macrocycle, forms a fused substituted or unsubstituted, saturated, partially saturated or unsaturated, cycle or heterocycle having 3 to 20 ring carbon atoms;
V, together with the adjacent carbon atoms of the macrocycle, forms a fused substituted or unsubstituted, saturated, partially saturated or unsaturated, cycle or heterocycle having 3 to 20 ring carbon atoms;
W, together with the nitrogen of the macrocycle and the carbon atoms of the macrocycle to which it is attached, forms an aromatic or alicyclic, substituted or unsubstituted, saturated, partially saturated or unsaturated nitrogen-containing fused heterocycle having 2 to 20 ring carbon atoms, provided that when W is a fused aromatic heterocycle the hydrogen attached to the nitrogen which is both part of the heterocycle and the macrocycle and R1 and R10 attached to the carbon atoms which are both part of the heterocycle and the macrocycle are absent;
X and Y represent suitable ligands which are derived from any monodentate or polydentate coordinating ligand or ligand system or the corresponding anion thereof;
Z is a counterion;
n is an integer from 0 to 3; and
the dashed lines represent coordinating bonds between the nitrogen atoms of the macrocycle and the transition metal, manganese.

### Claim at position 2

-8. (canceled)

### Claim 9 (depends on 1)

The method according to claim 1, wherein R1, R2, R′2, R3, R4, R5, R′5, R6, R′6, R7, R8, R9, R′9, and R10 are each hydrogen.

### Claim 10 (depends on 1)

The method according to claim 1, wherein W is an unsubstituted pyridine moiety.

### Claim 11 (depends on 1)

The method according to claim 1, wherein U and V are transcyclohexanyl fused rings.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the manganese-containing coordination complex comprises a structure according to Formula (II):
wherein
X and Y represent suitable ligands which are derived from any monodentate or polydentate coordinating ligand or ligand system or the corresponding anion thereof; and
RA, RB, RC, and RD are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclyl, an amino acid side chain moiety, or a moiety selected from the group consisting of —OR11, —NR11R12, —COR11, —CO2R11, —CONR11R12, —SR11, —SOR11, —SO2R11, —SO2NR11R12, —N(OR11)(R12), —P(O)(OR11)(OR12), —P(O)(OR11)(R12), and —OP(O)(OR11)(OR12), wherein R1 and R12 are independently hydrogen or alkyl.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the manganese-containing coordination complex is represented by Formula (III) or Formula (IV):
wherein
X and Y represent suitable ligands which are derived from any monodentate or polydentate coordinating ligand or ligand system or the corresponding anion thereof, and
RA, RB, RC, and RD are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclyl, an amino acid side chain moiety, or a moiety selected from the group consisting of —OR11, —NR11R12, —COR11, —COR11, —CONR11R12, —SR11, —SOR11, —SO2R11, —SO2NR11R12, —N(OR11)(R12), —P(O)(OR11)(OR12), —P(O)(OR11)(R12), and —OP(O)(OR11)(OR12), wherein R11 and R12 are independently hydrogen or alkyl.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the manganese-containing coordination complex is represented by a formula selected from the group consisting of Formulae (V)-(XVI):

### Claim 15 (depends on 1)

The method according to claim 1, wherein X and Y are independently selected from substituted or unsubstituted moieties of the group consisting of halide, oxo, aquo, hydroxo, alcohol, phenol, dioxygen, peroxo, hydroperoxo, alkylperoxo, arylperoxo, ammonia, alkylamino, arylamino, heterocycloalkyl amino, heterocycloaryl amino, amine oxides, hydrazine, alkyl hydrazine, aryl hydrazine, nitric oxide, cyanide, cyanate, thiocyanate, isocyanate, isothiocyanate, alkyl nitrile, aryl nitrile, alkyl isonitrile, aryl isonitrile, nitrate, nitrite, azido, alkyl sulfonic acid, aryl sulfonic acid, alkyl sulfoxide, aryl sulfoxide, alkyl aryl sulfoxide, alkyl sulfenic acid, aryl sulfenic acid, alkyl sulfinic acid, aryl sulfinic acid, alkyl thiol carboxylic acid, aryl thiol carboxylic acid, alkyl thiol thiocarboxylic acid, aryl thiol thiocarboxylic acid, alkyl carboxylic acid, aryl carboxylic acid, urea, alkyl urea, aryl urea, alkyl aryl urea, thiourea, alkyl thiourea, aryl thiourea, alkyl aryl thiourea, sulfate, sulfite, bisulfate, bisulfite, thiosulfate, thiosulfite, hydrosulfite, alkyl phosphine, aryl phosphine, alkyl phosphine oxide, aryl phosphine oxide, alkyl aryl phosphine oxide, alkyl phosphine sulfide, aryl phosphine sulfide, alkyl aryl phosphine sulfide, alkyl phosphonic acid, aryl phosphonic acid, alkyl phosphinic acid, aryl phosphinic acid, alkyl phosphinous acid, aryl phosphinous acid, phosphate, thiophosphate, phosphite, pyrophosphite, triphosphate, hydrogen phosphate, dihydrogen phosphate, alkyl guanidino, aryl guanidino, alkyl aryl guanidino, alkyl carbamate, aryl carbamate, alkyl aryl carbamate, alkyl thiocarbamate, aryl thiocarbamate, alkylaryl thiocarbamate, alkyl dithiocarbamate, aryl dithiocarbamate, alkylaryl dithiocarbamate, bicarbonate, carbonate, perchlorate, chlorate, chlorite, hypochlorite, perbromate, bromate, bromite, hypobromite, tetrahalomanganate, tetrafluoroborate, hexafluoroantimonate, hypophosphite, iodate, periodate, metaborate, tetraaryl borate, tetra alkyl borate, tartrate, salicylate, succinate, citrate, ascorbate, saccharinate, amino acid, hydroxamic acid, thiotosylate, and anions of ion exchange resins, or the corresponding anions thereof;
or X and Y correspond to —O—C(O)—X1, where each X1 is —C(X2)(X3)(X4), and
each X1 is independently substituted or unsubstituted phenyl or —C(—X2)(—X3)(—X4);
each X2 is independently substituted or unsubstituted phenyl, methyl, ethyl or propyl;
each X3 is independently hydrogen, hydroxyl, methyl, ethyl, propyl, amino, —X5C(═O)R13 where X5 is NH or O, and R13 is C1-C18 alkyl, substituted or unsubstituted aryl or C1-C18 aralkyl, or —OR14, where R14 is C1-C18 alkyl, substituted or unsubstituted aryl or C1-C18 aralkyl, or together with X4 is (═O); and
each X4 is independently hydrogen or together with X3 is (═O);
or X and Y are independently selected from the group consisting of charge-neutralizing anions which are derived from any monodentate or polydentate coordinating ligand and a ligand system and the corresponding anion thereof,
or X and Y are independently attached to one or more of R1, R2, R′2, R3, R4, R5, R′5, R6, R′6, R7, R8, R9, R′9, and R10.

### Claim 16 (depends on 1)

The method according to claim 1, wherein X and Y are independently selected from the group consisting of fluoro, chloro, bromo, and iodo anions.

### Claim 17 (depends on 1)

The method according to claim 1, wherein X and Y are independently selected from the group consisting of alkyl carboxylates, aryl carboxylates and arylalkyl carboxylates.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method according to claim 1, wherein the manganese-containing coordination complex is a compound represented by any of the following formulas:

### Claim at position 14

-24. (canceled)

### Claim 25 (depends on 1)

The method according to claim 1, wherein the manganese-containing coordination complex is represented by the formula:

### Claim 26

(canceled)

### Claim 27 (depends on 1)

The method according to claim 1, wherein the source of chloride anion comprises a salt capable of forming chloride anions in aqueous solution.

### Claim 28 (depends on 1)

The method according to claim 1, wherein the source of chloride anion comprises at least one selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, and magnesium chloride.

### Claim 29 (depends on 1)

The method according to claim 1, comprising adding an amount of the source of chloride anion that is sufficient to provide a concentration of chloride anion in the aqueous formulation of at least 100 mM, at least 110 mM, at least 115 mM, at least 120 mM, at least 130 mM, at least 145 mM and/or at least 150 mM, and no more than 1000 mM, no more than 200 mM, no more than 180 mM, no more than 175 mM, no more than 160 mM and/or no more than 155 mM.

### Claim 30 (depends on 1)

The method according to claim 1, wherein the source of dianion comprises a bicarbonate salt and/or a phosphate salt.

### Claim 31 (depends on 1)

The method according to claim 1, comprising adding an amount of the source of dianion that is sufficient to provide a concentration of the dianion in the aqueous formulation of at least 0.1 mM, at least 0.25 mM, at least 1 mM, and/or at least 2.5 mM, and no more than 26 mM, no more than 15 mM, and/or no more than 10 mM.

### Claim 32 (depends on 1)

The method according to claim 1, wherein the source of dianion comprises a buffering agent, and wherein the source of dianion is adding in an amount sufficient to buffer the aqueous formulation within a pH range of from 7 to 10, and/or a pH range of from 7.5 to 9.

### Claim 33 (depends on 1)

The method according to claim 1, wherein the concentration of chloride anion in the aqueous formulation exceeds the concentration of the dianion in the formulation by a ratio of the concentration in mol/L chloride anion to dianion of at least 10:1, at least 100:1, at least 250:1, at least 500:1, at least 750:1, at least 1000:1, at least 5000:1, and/or at least 10,000:1.

### Claim 34 (depends on 1)

The method according to claim 1, wherein at least 75 mol %, at least 85 mol %, at least 90 mol %, at least 95 mol %, at least 98 mol %, at least 99 mol %, and/or the entire molar amount of the source of dianion added to form the aqueous formulation is added simultaneously with or following combination of the source of chloride anion with the manganese-containing coordination complex.

### Claim 35 (depends on 1)

The method according to claim 1, wherein no amount of the source of dianion is combined with the manganese-containing coordination complex prior to combining the manganese-containing coordination complex and source of chloride anion.

### Claim 36 (depends on 1)

The method according to claim 1, wherein the source of dianion is added to the aqueous solution comprising the chloride anion and manganese-containing coordination complex at least 30 seconds, at least 1 minute, at least 5 minutes, at least 10 minutes, at least 30 minutes, and/or at least one hour after combining the manganese-containing coordination complex with the source of chloride anion in the aqueous solution.

### Claim 37 (depends on 1)

The method according to claim 1, further comprising bringing the aqueous solution to a pH of at least 8 prior to combining the manganese-containing coordination complex and source of chloride anion therein.

### Claim 38 (depends on 1)

The method according to claim 1, wherein the aqueous formulation comprises a buffered formulation for parenteral administration of the manganese-containing coordination complex, the buffered formulation having a physiological level of sodium chloride.

### Claim 39 (depends on 1)

The method according to claim 1, wherein a concentration of the manganese-containing coordination complex in the aqueous formulation is at least 2 mM, at least 6 mM, at least 18 mM, at least 20 mM, and/or at least 40 mM.

### Claim 40 (depends on 1)

An aqueous formulation comprising a manganese-containing coordination complex, the aqueous formulation prepared according to the method of claim 1.

### Claim 41 (depends on 1)

A method of treatment of a condition in a patient, comprising parenterally administering a buffered solution comprising the aqueous formulation of the manganese-containing coordination complex prepared according to the method of claim 1.

### Claim 42 (depends on 41)

The method of treatment according to claim 41, comprising intravenously administering the buffered solution comprising the manganese-containing coordination complex.

### Claim 43 (depends on 41)

The method of treatment according to claim 41, comprising parenterally administering the buffered solution comprising the manganese-containing coordinate complex to treat any selected from the group consisting of cancer, a cardiovascular disorder, a cerebrovascular disorder, a dermatological disorder, a fibrotic disorder, a gastrointestinal disorder, an immunological disorder, an inflammatory disorder, a metabolic disorder, a neurological disorder, an ophthalmic disorder, a pulmonary disorder, an infectious disease, and combinations thereof.

### Claim 44 (depends on 41)

The method of treatment according to claim 41, comprising parenterally administering the buffered solution comprising the manganese-containing coordinate complex to treat cancer and/or a radiation-induced tissue injury.

### Claim 45

A buffered formulation for parenteral administration of a manganese-containing pentaaza macrocyclic ring complex, the buffered formulation comprising:
a buffered aqueous solution comprising: (i) the manganese-containing pentaaza macrocyclic ring complex in a concentration of from 1 mg/mL to 50 mg/mL; (ii) sodium chloride in a concentration of from 130 mM to 160 mM; and (iii) a buffering agent comprising bicarbonate in a concentration sufficient to buffer the aqueous solution to a pH in the range of 7 to 10,
wherein a storage stability of the buffered formulation is such that no manganese-containing precipitate is detectable as measured via visual detection for 9 months following preparation of the buffered formulation, and
wherein the manganese-containing coordination complex comprises a pentaaza macrocyclic ring complex having a structure according to Formula (I)
wherein
M is Mn2+ or Mn3+;
R1, R2, R′2, R3, R4, R5, R′5, R6, R′6, R7, R8, R9, R′9, and R10 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclyl, an amino acid side chain moiety, or a moiety selected from the group consisting of —OR11, —NR11R12, —COR11, —CO2R11, —CONR11R12, —SR11, —SOR11, —SO2R11, —SO2NR11R12, —N(OR11)(R12), —P(O)(OR11)(OR12), —P(O)(OR11)(R12), and —OP(O)(OR11)(OR12), wherein R11 and R12 are independently hydrogen or alkyl;
U, together with the adjacent carbon atoms of the macrocycle, forms a fused substituted or unsubstituted, saturated, partially saturated or unsaturated, cycle or heterocycle having 3 to 20 ring carbon atoms;
V, together with the adjacent carbon atoms of the macrocycle, forms a fused substituted or unsubstituted, saturated, partially saturated or unsaturated, cycle or heterocycle having 3 to 20 ring carbon atoms;
W, together with the nitrogen of the macrocycle and the carbon atoms of the macrocycle to which it is attached, forms an aromatic or alicyclic, substituted or unsubstituted, saturated, partially saturated or unsaturated nitrogen-containing fused heterocycle having 2 to 20 ring carbon atoms, provided that when W is a fused aromatic heterocycle the hydrogen attached to the nitrogen which is both part of the heterocycle and the macrocycle and R1 and R10 attached to the carbon atoms which are both part of the heterocycle and the macrocycle are absent;
X and Y represent suitable ligands which are derived from any monodentate or polydentate coordinating ligand or ligand system or the corresponding anion thereof;
Z is a counterion;
n is an integer from 0 to 3; and
the dashed lines represent coordinating bonds between the nitrogen atoms of the macrocycle and the transition metal, manganese.

### Claim 46 (depends on 45)

The buffered formulation according to claim 45, wherein the visual detection storage stability of the buffered formulation is such that no manganese-containing precipitate is detectable as measured via visual detection after 1 day and/or after 6 days following formation of the buffered formulation.

### Claim 47 (depends on 45)

The buffered formulation according to claim 45, wherein an ICP-MS storage stability assay comprises filtering the buffered formulation through a 0.45 micrometer filter, washing the filter with pH 8.0 water, digesting the filter contents with nitric acid, and performing inductively coupled mass-spectrometry (ICP-MS) to detect manganese content of any precipitate, and where the amount of manganese measured by the ICP-MS storage stability assay after at least 1 day, at least 6 days, and/or at least 9 months is less than 1500 ppm, and/or even less than 1200 ppm.

### Claim 48 (depends on 45)

The buffered formulation according to claim 45, comprising bicarbonate in a concentration of from 20 mM to 30 mM.

### Claim 49

(canceled)
